PMID- 18631948
OWN - NLM
STAT- MEDLINE
DCOM- 20080826
LR  - 20131121
IS  - 1552-5279 (Electronic)
IS  - 1552-5260 (Linking)
VI  - 4
IP  - 1
DP  - 2008 Jan
TI  - One-week dose titration of extended release galantamine in patients with 
      Alzheimer's disease.
PG  - 30-7
LID - 10.1016/j.jalz.2007.10.013 [doi]
AB  - BACKGROUND: Our purpose was to assess the safety and tolerability of 
      extended-release galantamine (GAL-ER), using a 1-week dose titration in 
      Alzheimer's patients. METHODS: An open-label, 12-week, multicenter study was 
      performed (n = 82). Results were compared with findings from a placebo-controlled 
      trial using a 4-week titration of GAL-ER and immediate-release galantamine. The 
      primary analysis compared incidences of adverse events (AEs). RESULTS: Although 
      not statistically significant, more patients in the 1-week titration study 
      experienced an AE. More patients with a 1-week titration had at least one 
      prespecified gastrointestinal (GI) AE. These findings correlated with a higher 
      baseline incidence of GI disturbances. Four patients experienced serious AEs; no 
      deaths occurred. Mean Mini-Mental State Examination scores improved by 1.8 and 
      1.9 points at weeks 4 and 12, respectively. CONCLUSIONS: A 1-week titration of 
      GAL-ER was generally safe and well tolerated, with a potential risk of more GI 
      side effects. A 1-week titration may permit dosing flexibility and promote 
      increased adherence to medication regimens.
FAU - Scharre, Douglas W
AU  - Scharre DW
AD  - Division of Cognitive Neurology, Department of Neurology, Ohio State University, 
      Columbus, OH, USA.
FAU - Shiovitz, Thomas
AU  - Shiovitz T
FAU - Zhu, Young
AU  - Zhu Y
FAU - Amatniek, Joan
AU  - Amatniek J
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Multicenter Study
PT  - Research Support, Non-U.S. Gov't
DEP - 20071221
PL  - United States
TA  - Alzheimers Dement
JT  - Alzheimer's & dementia : the journal of the Alzheimer's Association
JID - 101231978
RN  - 0 (Cholinesterase Inhibitors)
RN  - 0D3Q044KCA (Galantamine)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Alzheimer Disease/*drug therapy
MH  - Cholinesterase Inhibitors/*administration & dosage/adverse effects
MH  - Dose-Response Relationship, Drug
MH  - Drug Administration Schedule
MH  - Female
MH  - Galantamine/*administration & dosage/adverse effects
MH  - Humans
MH  - Male
MH  - Middle Aged
EDAT- 2008/07/18 09:00
MHDA- 2008/08/30 09:00
CRDT- 2008/07/18 09:00
PHST- 2007/04/17 00:00 [received]
PHST- 2007/09/11 00:00 [revised]
PHST- 2007/10/25 00:00 [accepted]
PHST- 2008/07/18 09:00 [pubmed]
PHST- 2008/08/30 09:00 [medline]
PHST- 2008/07/18 09:00 [entrez]
AID - S1552-5260(07)00638-3 [pii]
AID - 10.1016/j.jalz.2007.10.013 [doi]
PST - ppublish
SO  - Alzheimers Dement. 2008 Jan;4(1):30-7. doi: 10.1016/j.jalz.2007.10.013. Epub 2007 
      Dec 21.